US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Agenus Inc. - Common Stock (NQ:AGEN)

8.360 +0.030 (+0.36%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Agenus Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Agenus (NASDAQ:AGEN) Passes Minervini Trend Template with High Growth Momentum ↗
Via Chartmill
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
Discover the most active stocks in Monday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session. The market value of their outstanding shares is at $139.5 million. Q32 Bio (NASDAQ:QTTB) stock rose... 
Via Benzinga
Top stock movements in today's session. ↗
Via Chartmill
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Examining the Future: Agenus's Earnings Outlook ↗
 
Via Benzinga
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing ↗
Agenus (NASDAQ:AGEN) said it is shifting its development focus and financial resources toward a Phase 3 registrational trial of neoadjuvant botensilimab plus balstilimab, known as BOT/BAL, in high-risk... 
Via MarketBeat
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves ↗
Agenus (NASDAQ:AGEN) told shareholders at its 2026 virtual annual meeting that it remains focused on advancing its botensilimab and balstilimab immunotherapy combination, known as BOT/BAL, while... 
Via MarketBeat
News headline image
Agenus (AGEN) Q2 2025 Earnings Call Transcript ↗
Agenus (AGEN) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Thursday's session: top gainers and losers ↗
Via Chartmill
Which stocks are moving on Thursday? ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Agenus (AGEN) Q3 2024 Earnings Call Transcript ↗
Agenus (AGEN) Q3 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Agenus (AGEN) Q1 2025 Earnings Call Transcript ↗
Agenus (AGEN) Q1 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Agenus (AGEN) Q4 2024 Earnings Call Transcript ↗
Agenus (AGEN) Q4 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
AGENUS INC (NASDAQ:AGEN) Reports Mixed Q3 2025 Earnings, Driven by One-Time Gain ↗
Agenus reports mixed Q3 2025 results with a revenue miss but strong clinical progress for its cancer drug BOT/BAL, including a new Phase 3 trial. 
Via Chartmill
News headline image
Insights Ahead: Agenus's Quarterly Earnings ↗
 
Via Benzinga
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025.... 
Via MarketMinute
Topics Intellectual Property
News headline image
Monday's pre-market session: top gainers and losers ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Agenus Posts 48% Q2 Revenue Miss ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang ↗
Zydus acquires two Agenus biologics facilities in California for $75 million, expanding U.S. CDMO presence and securing rights to key cancer drug manufacturing. 
Via Benzinga
News headline image
Agenus Stock Is Trading Higher Tuesday: What's Going On? ↗
Agenus announced it signed a partnership agreement with Zydus Lifesciences to expand patient access to Botensilimab and Balstilimab. 
Via Benzinga
News headline image
Tuesday's pre-market session: top gainers and losers ↗
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
Earnings Scheduled For August 11, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >